The convertible senior notes are due 2028

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A offering by TransMedics Group, Inc. of $460 million aggregate principal amount of 1.50% convertible senior notes due 2028, which included $60 million aggregate principal amount of notes from the full exercise of the initial purchasers’ option to purchase additional notes. In addition, Davis Polk advised the counterparties to capped call transactions entered into in connection with the offering. TransMedics’ common stock is listed on the Nasdaq Global Market under the symbol “TMDX.”

TransMedics Group, Inc. is a commercial-stage medical technology company that is transforming organ transplant therapy for end-stage organ failure patients across multiple disease states.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Jakub P. Jozwiak and Kanger Jin. The equity derivatives team included partners Mark M. Mendez and Caitlin L. Wood, counsel Joseph Luizzi and Hanbing Zhang and associates Eugenia S. Lee and Amy Cheng. All members of the Davis Polk team are based in the New York office.